Harmony Biosciences Holdings Inc. has announced an exclusive licensing agreement with Bioprojet Pharma SAS to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin OX2 receptor agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders.
Researchers from Bristol Myers Squibb Co. have published details on the discovery and characterization of novel protease-activated receptor 4 (PAR4) antagonists as potential antiplatelet therapy candidates.
BLR Bio LLC announced that the U.S. FDA has granted orphan drug designation to BLR-200, the company’s investigational therapy for the treatment of systemic sclerosis (SSc).
Researchers from Second Military Medical University PLA (Shanghai) and affiliated organizations announced the discovery and preclinical characterization of novel antifungal small-molecule candidates.
Recent work at Southern Medical University, Guangzhou, focused on the discovery and synthesis of imidazoquinoline-based Toll-like receptor 7 (TLR7) agonists as potential candidates for the treatment of melanoma.
Lamassu Biotech Inc. has announced that its IND for SA53-OS has been cleared by the FDA in the U.S. The planned phase I/IIa trials will investigate the genetically targeted therapy that blocks the MDM2 protein, a key regulator of the tumor suppressor p53 gene.
The FDA has granted orphan drug designation to the active ingredient in Soligenix Inc.’s Suvax, a subunit protein vaccine of recombinantly expressed Sudan ebolavirus (SUDV) glycoprotein, for the prevention and post-exposure prophylaxis against SUDV infection. SUDV is a type of ebolavirus for which there is no current treatment or vaccine.
Results of preclinical studies with a highly potent KRAS (G12D mutant) inhibitor for the treatment of cancer were recently reported by researchers from Betta Pharmaceuticals Co. Ltd. BPI-501836 displayed higher inhibitory activity at KRAS G12D, when compared to the reference compound (IC50=0.25 and 2.4 nM, respectively) in NanoBRET assays.
The Scripps Research Institute has disclosed Ras-related protein Rab-27A/synaptotagmin-like protein 1 (SYTL1; JFC1) interaction inhibitors reported to be useful for the treatment of endotoxemia, sepsis, systemic inflammatory response syndrome and cryopyrin-associated periodic syndromes (CAPS).
RSS
